Protagonist Therapeutics (PTGX) Current Deferred Revenue: 2017-2025
Historic Current Deferred Revenue for Protagonist Therapeutics (PTGX) over the last 7 years, with Sep 2025 value amounting to $14.2 million.
- Protagonist Therapeutics' Current Deferred Revenue fell 60.77% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 60.77%. This contributed to the annual value of $18.9 million for FY2024, which is 629600.00% up from last year.
- As of Q3 2025, Protagonist Therapeutics' Current Deferred Revenue stood at $14.2 million, which was down 3.32% from $14.7 million recorded in Q2 2025.
- Protagonist Therapeutics' 5-year Current Deferred Revenue high stood at $45.0 million for Q1 2024, and its period low was $3,000 during Q3 2023.
- Over the past 3 years, Protagonist Therapeutics' median Current Deferred Revenue value was $16.9 million (recorded in 2025), while the average stood at $20.8 million.
- Its Current Deferred Revenue has fluctuated over the past 5 years, first slumped by 98.57% in 2022, then skyrocketed by 1,206,566.67% in 2024.
- Quarterly analysis of 5 years shows Protagonist Therapeutics' Current Deferred Revenue stood at $1.6 million in 2021, then plummeted by 95.69% to $69,000 in 2022, then crashed by 95.65% to $3,000 in 2023, then skyrocketed by 629,600.00% to $18.9 million in 2024, then slumped by 60.77% to $14.2 million in 2025.
- Its last three reported values are $14.2 million in Q3 2025, $14.7 million for Q2 2025, and $16.9 million during Q1 2025.